Protagonist Therapeutics Inc (PTGX) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.

Total Revenue Chart for Protagonist Therapeutics Inc

Protagonist Therapeutics Inc (PTGX) revenue for FY2025 was USD 46.0M, a -89.4% change from FY2024. Protagonist Therapeutics Inc's revenue moved from USD 0.00 in 2014 to USD 46.0M in 2025 over 11 years. Earnings per share moved from USD -1.91 in 2014 to USD -2.60 in 2022. Revenue compound annual growth rate: 5-year CAGR of 10.0%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Compare with

Key Stats

Market Cap
$8.96B
Implied Share Price
$138.43
Enterprise Value
$8.47B
Revenue (TTM)
$281.99M
EBITDA
$59.88M
Profit Margin
29.40%
Trailing P/E
134.40
Forward P/E
36.90
Price/Book (MRQ)
11.00
Price/Sales (TTM)
31.77
EV/EBITDA
141.64
EV/Revenue
30.08
Dividend Yield
—
Book Value
$13.01
Free Cash Flow (FY2025)
$56.08M
Free Cash Flow Yield
0.63%

Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.